AXYNTIS
AXYNTIS is a French independent fine chemistry CDMO operating 6 manufacturing sites, providing GMP-compliant custom API synthesis, generic APIs, HPAPIs, and chromatography services primarily to pharmaceutical and cosmetic clients, with over 70% of revenue exported internationally.
- Company typePrivate
- Founded2007
- HeadquartersParis, France
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What AXYNTIS does
AXYNTIS is a French independent fine chemistry CDMO founded in 2007 and headquartered in Paris, operating as the largest independent multi-site fine chemistry group in France with 6 manufacturing sites and 3 R&D centers across the country. The company is organized into specialized subsidiaries: Orgapharm (Pithiviers, advanced intermediates and APIs with chromatography and HPAPI capabilities), Centipharm (Grasse, generic APIs with DMF/CEP regulatory dossiers), Kyrapharm (preparative chromatography), Steiner (Saint-Marcel, dyes for paper and petroleum industries), and Synthexim (Calais, acquired from Calaire Chimie in 2013). Its technology stack spans fine chemistry synthesis from laboratory (Kilolab) to industrial GMP-compliant scale, with specialized capabilities in preparative chromatography, hydrogenation, HPAPI synthesis, and emerging bioproduction (MIAMI project for microbial cell factory-based alkaloid production, developed with Université de Tours and John Innes Center).
The company operates a B2B contract manufacturing model serving pharmaceutical companies (custom API synthesis, generic APIs, HPAPIs for anticancer drugs, clinical lot manufacturing — ~50% of revenue), cosmetics and fragrance firms (specialty chemical intermediates), and industrial colorant buyers (paper and petroleum sectors via the Steiner division). Revenue is project-specific and quote-based under CDMO contracts, with over 70% of revenue generated from international exports. Key customers include Innova Medical Group (COVID-19 rapid antigen test production at 5 million units/month capacity) and Provepharm Life Solutions (Proveblue/methylene blue production at Pithiviers). The company is strategically positioned within French pharmaceutical sovereignty initiatives, having secured two France Relance awards in 2021 (8M€ investment, 3.6M€ from BPI/PIA, projecting 16M€ incremental annual revenue) for HPAPI manufacturing and API reshoring. Founder David Simonnet controls the capital, with Japanese partner Fuji Silysia holding an equity stake, and no public listing or institutional PE/VC backing is disclosed.
AXYNTIS firmographics
Firmographics- Name
- AXYNTIS
- Legal name
- Axyntis Group
- Website
- https://axyntis.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- AXYNTIS is a French independent fine chemistry CDMO operating 6 manufacturing sites, providing GMP-compliant custom API synthesis, generic APIs, HPAPIs, and chromatography services primarily to pharmaceutical and cosmetic clients, with over 70% of revenue exported internationally.
- Ownership category
- akta.pro rank
AXYNTIS industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industries
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where AXYNTIS is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices4 records
Markets served
AXYNTIS business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales
Revenue model
- CDMO Contract Manufacturing Services: As a CDMO (Contract Development and Manufacturing Organization), AXYNTIS earns revenue through contract manufacturing services for pharmaceutical and cosmetic companies, developing and producing custom molecules and APIs under GMP conditions for third-party clients. This represents the majority of revenue.
- Product Sales (Intermediates, APIs, Specialty Chemicals):
Go-to-market motion2 records
Distribution channels1 record
Marketing channels7 records
AXYNTIS product offering
Product offeringCore offering
AXYNTIS is a French independent fine chemistry group operating as a Contract Development and Manufacturing Organization (CDMO). The company manufactures active pharmaceutical ingredients (APIs), advanced intermediates, generic APIs, high-potency APIs (HPAPIs), specialty chemicals, and industrial dyes/colorants across six manufacturing sites in France, serving pharmaceutical, cosmetic, and industrial customers.
Differentiator
Problem solved
Functional benefit
Brands
- Orgapharm: Subsidiary specializing in advanced intermediates and active pharmaceutical ingredients production, plus chromatography services
- Centipharm
- Steiner
- Kyrapharm
- Synthexim
Products and services
- CDMO Contract Manufacturing Services Contract development and manufacturing organization services spanning the full lifecycle from R&D and process development through pilot and industrial-scale production for pharmaceutical and fine chemical clients.
- Active Pharmaceutical Ingredients (APIs) Custom and catalog production of active pharmaceutical ingredients for originator and generic drug manufacturers.
- High-Potency API (HPAPI) Manufacturing Specialized manufacturing of high-potency active pharmaceutical ingredients under contained conditions for oncology and other sensitive therapeutic applications.
- Generic APIs Production of generic active pharmaceutical ingredients accompanied by Drug Master Files (DMF) and Certificates of Suitability (CEP) for regulatory submissions.
- Preparative Chromatography Services Custom purification services using preparative chromatography techniques, scaling from lab to industrial batch sizes for pharmaceutical and fine chemical applications.
- Industrial Dyes and Colorants Production of specialty dyes and colorants for industrial applications including paper manufacturing, petroleum, ink, textile, and detergent sectors.
- Hydrogenation Services Industrial hydrogenation reactions and custom synthesis services used in the production of pharmaceutical intermediates and APIs.
- Advanced Chemical Intermediates Manufacture of advanced chemical intermediates used as building blocks in pharmaceutical synthesis and fine chemistry.
- Natural Vindoline Production Biosynthetic production of natural vindoline, a vinca alkaloid intermediate used as a precursor in anti-cancer drug synthesis.
- Specialty Cosmetic Ingredients Manufacture of specialty chemical ingredients such as dimethyl sulfone, methylsulfonylmethane, and antioxidant actives for the cosmetics and personal care industry.
Quantifiable outcome
- 5 million COVID-19 antigen tests produced per month at Pithiviers for Innova Medical Group
- +3 more outcomes
Companies that use AXYNTIS
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
AXYNTIS technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
AXYNTIS partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core.
- Innova Medical GroupcoreAxyntis produces rapid COVID-19 antigen detection tests for California-based Innova Medical Group at its Pithiviers site (Orgapharm). The partnership reached capacity of 5 million tests/month, described as a long-term implantation by both parties. Axyntis as manufacturer/producer for IMG's products.
- MIAMI Project ConsortiumcoreAxyntis is a partner in the MIAMI (Monoterpenoid Alkaloids in Microbial cell factories) project, a research initiative developing tools and methodologies to discover complex plant biosynthetic pathways and optimize production in microbes. This represents Axyntis's strategic entry into bioproduction.
- Provepharm Life SolutionscoreAxyntis signed a new agreement with Provepharm Life Solutions for the production of Proveblue (methylene blue pharmaceutical product) on the Pithiviers platform. Dedicated investment to increase production capacity, particularly for European and American markets.
- Nippon Chemicals (Japan)coreStrategic partnership signed during CPhI with Nippon Chemicals (a listed Japanese group) to develop phosphorated ligand chemistry within Axyntis's production facilities. This represents a technology development partnership in a specialized chemistry domain.
- Université de Tours / John Innes CentercoreCollaboration with the Biomolecules et Biotechnologies Végétales (BBV) laboratory at Université de Tours and the John Innes Center (Norwich, UK) for the development of natural vindoline production through microbial cell factories, enabling anticancer drug development independent of Madagascar periwinkle plant supply.
- Fuji Silysia (Japan)coreStrategic alliance with Japanese group Fuji Silysia, which holds a stake alongside founder David Simonnet. The partnership includes joint R&D (construction of a dedicated silica grafted R&D laboratory for chromatography applications) and is described as a long-term strategic alliance supporting Axyntis's chromatography and specialty silica activities.
Scale indicators9 records
Recent moves10 records
Expansion highlights7 records
AXYNTIS competitors and assessment
Company assessmentDirect peers
- Novasep: French CDMO specializing in active pharmaceutical ingredients, HPAPIs, and chromatography-based purification — closely matches Axyntis's HPAPI and preparative chromatography capabilities, both with European manufacturing footprints.
- Fareva: Major French CDMO/CMO serving pharmaceutical and cosmetic industries with custom synthesis and formulation — overlapping customer base (pharma + cosmetics) and similar European manufacturing footprint to Axyntis.
- Minakem: French specialty CDMO focused on complex API synthesis, HPAPIs, and high-containment manufacturing — directly comparable in scale, French base, and HPAPI specialization to Axyntis's Pithiviers platform.
- Seqens: French-headquartered global CDMO and API manufacturer offering custom synthesis, generics, and specialty ingredients across pharmaceutical, cosmetic, and industrial end markets — directly comparable to Axyntis's fine chemistry CDMO model and customer base.
- PCAS (now part of Seqens group): French fine chemicals and API manufacturer historically grouped with Axyntis and Sanofi Chimie in the 'top 3' French third-party API producers — directly comparable in custom synthesis, generic APIs, and pharmaceutical intermediates.
Broad incumbents
- Catalent: Global CDMO serving pharmaceutical and consumer health with custom API and drug product development — comparable CDMO business model though at much larger scale and broader service offering than Axyntis.
- Lonza: Swiss-headquartered global CDMO leader in API and biologics manufacturing — comparable in HPAPI and custom synthesis capabilities, though at a vastly larger scale spanning many more therapeutic areas.
- Sanofi Chimie: Captive fine chemicals/API arm of Sanofi historically cited alongside Axyntis in France's top-3 third-party API producers — operates at much larger scale as an integrated pharma manufacturer, but comparable in chemistry capability and French footprint.
Emerging players
- Cambrex: Mid-sized CDMO specializing in small-molecule APIs, controlled substances, and HPAPIs — directly comparable in scale, custom synthesis focus, and HPAPI capability, though US-headquartered rather than European.
- WuXi STA (WuXi AppTec): Asia-based global CDMO with extensive small-molecule API and intermediate manufacturing capacity — competing with Axyntis in the same CDMO space, particularly for European pharma customers seeking offshore API production.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
AXYNTIS social profiles
Digital presenceAXYNTIS financial estimates
Financial estimateRevenue estimate
Valuation estimate
AXYNTIS leadership team
Management profileNumber of profiles
Profiles1 record
AXYNTIS subsidiaries and ownership
Company hierarchySubsidiaries6 records
AXYNTIS funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AXYNTIS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AXYNTIS
What does AXYNTIS do?
AXYNTIS is a French independent fine chemistry group operating as a Contract Development and Manufacturing Organization (CDMO). The company manufactures active pharmaceutical ingredients (APIs), advanced intermediates, generic APIs, high-potency APIs (HPAPIs), specialty chemicals, and industrial dyes/colorants across six manufacturing sites in France, serving pharmaceutical, cosmetic, and industrial customers.
Is AXYNTIS a public or private company?
AXYNTIS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was AXYNTIS founded?
AXYNTIS was founded in 2007. It employs 251 to 500 people.
Where is AXYNTIS based?
AXYNTIS is headquartered in Paris, France, in the Europe region.
How does AXYNTIS make money?
Two revenue lines are on record. CDMO Contract Manufacturing Services are the primary driver. The others are product Sales (Intermediates, APIs, Specialty Chemicals).
Who are AXYNTIS's main competitors?
Direct peers on record are Novasep, Fareva, Minakem, Seqens and PCAS (now part of Seqens group). Broad incumbents are Catalent, Lonza and Sanofi Chimie. Emerging players are Cambrex and WuXi STA (WuXi AppTec).
Does AXYNTIS have an API?
No public API is recorded for AXYNTIS.
What industry is AXYNTIS in?
AXYNTIS's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 3254 and its SIC code is 2833.